Developed by a team of scientists at the Weizmann
Institute in Israel, a procedure called Tookad® Vascular-Targeted Photodynamic
Therapy, or Tookad® VTP, has proven itself through clinical trials to cure up
to 80% of early stage prostate cancer patients. Doing so without any of the
debilitating, life-threatening side effects so often resulting from surgery,
radiation, and chemotherapy. The outpatient procedure takes less than 90
minutes. During this time a nature-based photosensitized drug called Tookad®
Soluble made from aquatic bacteriochlorophyll is injected. Then very thin optic
fibers are inserted into the cancerous tissue. The fibers are used to transmit
near-infrared light directly to the cancer site. Light plus Tookad® Soluble in
cancer cells immediately creates oxygen radicals and nitric oxide radicals, causing
the closure of cancer cell blood supply lines. Without nutrients, the cancer
cells die. Then the dead cancer cells along with any extra Tookad® Soluble are
naturally flushed out of the body without damage to healthy tissue or side
effects.
Tookad® VTP research is expanding to include many
different forms of cancer. Clinical trials are ongoing at New York’s Sloan
Kettering Cancer Center. For now, thanks to a clinical trial with 80 patients
from Mexico, Peru, and Panama the procedure is fully approved and available in
Mexico. A European Trial has recently concluded with 47 medical centers
enrolling over 400 patients.
Results confirmed, “Tookad® VTP was effective at reducing rates of
progression, conferring a negative biopsy status, and diminishing the need for
radical therapy.” In the U.S. a small, recently completed 2016 Trial confirmed a 73.3% cure rate with optimal dosing. For prostate cancer patients, and most likely many other forms of cancer,
Tookad® VTP with its current success rate and lack of side effects is a medical
miracle.
With its success rate; easy, safe, and short treatment process; and
lack of side effects, one has to wonder why this isn’t already the treatment of
choice for early prostate cancer.
Let’s take it one step
further. By combining Tookad® VTP with more effective early detection
procedures such as ONCOblot and nature-based pre-treatments such as Artesunate,
also employing an oxidative process to kill cancer, along with immune
modulators such as Thymogen to boost immune system activity, I believe we could
relegate deaths from prostate cancer to a mere footnote in history. Look for
more information about this procedure to follow soon.
No comments:
Post a Comment